Stockscreener 앱 받기
6.23
18.44%
0.97
시간 외 거래:
6.06
-0.17
-2.73%
Nextcure Inc 주식(NXTC)의 최신 뉴스
NextCure stock soars after positive data for bone disease treatment - Investing.com India
NextCure Soars On Encouraging Preclinical Data Of Brittle Bone Disease Drug Candidate - Nasdaq
NextCure Inc. Stock Analysis and ForecastPhenomenal returns - Autocar Professional
Is NextCure Inc. a good long term investmentExceptional trading results - PrintWeekIndia
What analysts say about NextCure Inc. stockSuperior return velocity - PrintWeekIndia
NextCure Stock Soars After-Hours On Promising Preclinical Data For Rare Bone Disease Treatment - MSN
Nextcure Stock Skyrockets Nearly 45% In After-Hours Trading After Sharing Preclinical Data For Brittle Bone Disease - Benzinga
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta - The Manila Times
What drives NextCure Inc. stock priceSuperior stock growth - Autocar Professional
What makes NextCure Inc. stock price move sharplyConsistent Growth Alert - Newser
Why NextCure Inc. stock attracts strong analyst attentionFree Access to Community - Newser
How NextCure Inc. stock performs during market volatilitySecure Your Capital Strategy - Newser
Piper Sandler lowers NextCure stock price target to $15 after reverse split By Investing.com - Investing.com South Africa
Piper Sandler lowers NextCure stock price target to $15 after reverse split - Investing.com India
NextCure initiates one-for-twelve reverse stock split on Nasdaq By Investing.com - Investing.com Nigeria
NextCure Implements Reverse Stock Split on Nasdaq - TipRanks
NextCure initiates one-for-twelve reverse stock split on Nasdaq - Investing.com
NextCure Announces One-for-Twelve Reverse Stock Split - TipRanks
NextCure announces 1-for-12 reverse stock split effective July 14 - Investing.com Nigeria
NextCure announces 1-for-12 reverse stock split effective July 14 By Investing.com - Investing.com South Africa
Analysts Offer Insights on Healthcare Companies: NextCure (NXTC), Lexaria Bioscience (LEXX) and Travere Therapeutics (TVTX) - The Globe and Mail
NextCure’s (NXTC) Buy Rating Reaffirmed at HC Wainwright - Defense World
Eyes on Asia: AstraZeneca, NextCure, Sagimet Biosciences - BioXconomy
Nextcure Inc: Analyzing NXTC Stock Trends - investchronicle.com
1.00%
0.15%
자본화:
|
볼륨(24시간):